Highlights Oxurion NV

Equities

OXUR

BE0003846632

Market Closed - Euronext Bruxelles Other stock markets 11:29:32 2024-05-08 EDT			5-day change	1st Jan Change
0.0001 ^EUR	0.00%		0.00%	-88.89%

04-12	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-06	Oxurion Raises Additional Funds from Convertible Bonds Issue	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023	04-11	CI
Oxurion Seeks Healthcare Mergers Under New Corporate Strategy	01-23	MT
Belgium's Oxurion Secures Funding, Evades Bankruptcy; CEO/CFO to Step Down	12-29	MT
Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema	11-20	CI
Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema	23-05-25	CI
Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-26	CI
Oxurion NV Provides Update on Recruitment for Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor THR 149 in Diabetic Macular Edema	23-03-14	CI
Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis	22-12-14	CI
Oxurion NV Announces Interim Analysis for KALAHARI Trial	22-11-18	CI
Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-05	CI
Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022	22-06-07	CI
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema	22-05-09	CI
Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting	22-04-11	CI
Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-22	CI
Oxurion NV Announces New Data on THR-149 Phase 2 Clinical Trial in DME At the Angiogenesis, Exudation, and Degeneration 2022 Conference	22-02-14	CI
Oxurion Provides Update on Clinical Pipeline Progress	22-01-07	CI
Oxurion Nv Announces the First Patient Has Been Dosed in Part B of Its Two-Part, Phase 2 Study Evaluating Multiple Injections of Thr-149 for the Treatment of DME	21-11-15	CI
Oxurion NV Announces First Patient Dosed in Its Phase 2 Study Evaluating THR-687 for the Treatment of Diabetic Macular Edema	21-10-13	CI
OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema	21-09-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oxurion NV

Equities

OXUR

BE0003846632

Highlights

Filters